FDA Guidance on Bioresearch Monitoring Inspections

FDA has released an updated guidance outlining its processes for bioresearch monitoring (BIMO) inspections, which oversee the conduct, reporting, and postmarketing activities of FDA-regulated clinical and nonclinical studies. The guidance clarifies how the agency evaluates compliance, interacts with establishments, and manages electronic records, both domestically and internationally.

BIMO inspections are part of a broader FDA program aimed at ensuring the integrity of data submitted in support of regulatory submissions and protecting the rights and safety of trial participants. Under the program, the FDA may access records, inspect facilities, and review electronic information systems to verify compliance with statutory requirements and agency regulations.

The guidance details the types of inspections conducted, including pre-announced, unannounced, comprehensive, or targeted evaluations. The FDA also noted the use of Remote Regulatory Assessments, a risk-based remote review of records and systems, which can sometimes substitute for on-site inspections.

For international sites, the FDA emphasizes that inspections are generally consistent with domestic procedures, though pre-announcement practices may differ due to country-specific clearance requirements. The agency also continues to collaborate with foreign regulatory authorities to conduct joint inspections and share information, aiming to harmonize oversight and reduce burdens on sponsors.

The guidance provides detailed recommendations on communication before, during, and after inspections. Establishments should ensure appropriate staff and records are available, facilitate access to electronic systems, and engage with inspectors to clarify requests. Following an inspection, FDA investigators may issue Form FDA 483 observations, which notify management of objectionable conditions or practices identified during the inspection. While responses are voluntary, the agency encourages establishments to submit written corrective and preventive action plans within 15 business days to potentially influence subsequent regulatory decisions.

The guidance also describes best practices for written responses to FDA observations, including addressing each observation separately, noting agreement or disagreement, outlining corrective actions with timelines, and submitting supporting documentation.